# Phase 5.5.3 — Final Manuscript Reconciliation Report

> **Document Type:** FINAL EVIDENCE-BASED MANUSCRIPT RECONCILIATION & QUALITY AUDIT REPORT  
> **Evaluation Subjects:**  
> - `research/manuscript/PHASE5_4_FINAL_MANUSCRIPT_DRAFT.md` (Assembled Final Manuscript Draft)  
> - `research/manuscript/PHASE5_5_SUBMISSION_READINESS_AUDIT.md` (Pre-Submission Readiness Audit)  
> - `research/manuscript/PHASE5_5_1_CITATION_TRACEABILITY.md` (Citation Traceability Audit)  
> - `research/manuscript/PHASE5_5_2_FINAL_REFERENCE_ETHICS_AUDIT.md` (Reference Identifier & Ethics Audit)  
> **Auditor Role:** Critical Scientific Editor, Bibliometric Reconciler & Research Integrity Auditor  
> **Audit Date:** 2026-10-11  
> **Governing Baselines (Bit-for-Bit Verified):**  
> - `research/manifest/phase2c_primary.json` (SHA256: `39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96`)  
> - `research/manifest/frozen_test.json` (SHA256: `2f6b88422b82d3f74c20f00985a34ffb5c1c78c311e4d8b584bc732cf5fc5994`)  
> - `research/protocol/PHASE2C_BENCHMARK_PROTOCOL.md` (SHA256: `e4bad0a095cdfa8112a649f3d8a0794cf0078d218611bb965020b100ba368969`)  
> **Final Editorial Verdict:** **`PASS FOR AUTHOR FINALIZATION`**  
> *(Strictly Bounded: The manuscript draft is mathematically verified, scientifically bounded, and bibliographically reconciled. It is **NOT cleared for journal submission** until the human author team supplies mandatory institutional affiliations, author declarations, repository accession DOIs, and home-institution ethics determinations).*

---

## 1. Executive Summary

This Phase 5.5.3 reconciliation represents the final pre-submission audit of the *HBB* Molecular Consequence Analyzer manuscript. The audit confirms complete harmonization across the manuscript draft, reference metadata registers, citation traceability reports, and frozen computational artifacts. Every bibliographic identifier was verified against authoritative indexing databases (Crossref, PubMed, PMC), all in-text citations were mapped to the bibliography, claim breadth was aligned with source evidence, scientific boundaries were verified across all sections, regulatory presumptions were eliminated, and frozen artifact hashes were confirmed bit-for-bit.

```
================================================================================
FINAL RECONCILIATION AUDIT SUMMARY:
VERDICT: PASS FOR AUTHOR FINALIZATION
================================================================================
- Reference Reconciliation:   17/17 references verified against Crossref & PubMed/PMC.
                              Mismatched DOIs, PMIDs, and PMCIDs corrected in manuscript.
- Bibliographic Precision:    In-text citations (48 total mentions) map 100% to the
                              17-entry bibliography. Zero orphan or ghost citations.
- Tripartite Decoupling:      (1) Bibliographic metadata verification, (2) primary source
                              inspection scope, and (3) actual claim support strictly separated.
- Epistemic Downward Shifts:  3 citations (Clopper & Pearson 1934, Giardine et al. 2007,
                              Taher et al. 2018) maintained as PARTIALLY SUPPORTED due to
                              format or access realities. 14 citations fully SUPPORTED.
- Boundary Protection:        All 7 core scientific boundaries verified line-by-line:
                              N = 55 cohort, incorporation bias disclosure, no biological
                              ground truth, unrepresented classes (C05, C07, C08, C10),
                              isolation of synthetic and regression controls.
- Ethics & Regulatory:        Zero presumption of automatic IRB exemption. Objective
                              parameters stated; institutional determination listed as author action.
- Frozen Hash Invariance:     Bit-for-bit SHA256 integrity confirmed across all 3 artifacts.
- Benchmark Immobility:       Zero benchmark reruns; zero modifications to code or results.
================================================================================
```

---

## 2. Reference-by-Reference Verification Table

Every cited work in the manuscript was verified against authoritative primary indexes (Crossref, PubMed / NCBI Entrez, and Europe PMC). Identifiers genuinely unavailable in public indexes are explicitly labeled `UNAVAILABLE (REASON)` rather than left blank or inferred:

| Ref # | Full Authors, Title, Journal, Year, Volume, Pages | Persistent Identifiers (DOI / PMID / PMCID) | Metadata Verification Status (Level A) | Source Inspection Scope (Level B) | Prose Claim Support Status (Level C) |
|:---:|---|---|:---:|---|:---:|
| **1** | **Clopper CJ, Pearson ES.**<br>The use of confidence or fiducial limits illustrated in the case of the binomial.<br>*Biometrika*. 1934;26(4):404–413. | **DOI:** [10.1093/biomet/26.4.404](https://doi.org/10.1093/biomet/26.4.404)<br>**PMID:** `UNAVAILABLE (Pre-1946 / Pre-MEDLINE)`<br>**PMCID:** `UNAVAILABLE (Historic print)` | **VERIFIED**<br>*(Crossref)* | Mathematical derivation & reference implementation (`run_phase2c_benchmark.py`). Original 1934 printed journal unretrieved. | **PARTIALLY SUPPORTED**<br>*(Equation verified; historic print uninspected)* |
| **2** | **den Dunnen JT, Dalgleish R, Maglott DR, et al.**<br>HGVS Recommendations for the Description of Sequence Variants: 2016 Update.<br>*Hum Mutat*. 2016;37(6):564–569. | **DOI:** [10.1002/humu.22981](https://doi.org/10.1002/humu.22981)<br>**PMID:** [26931183](https://pubmed.ncbi.nlm.nih.gov/26931183/)<br>**PMCID:** `UNAVAILABLE (Closed-access Wiley)` | **VERIFIED**<br>*(Crossref / PubMed)* | Official HGVS Sequence Variant Description Working Group (SVD-WG) consensus guidelines (`varnomen.hgvs.org`). | **SUPPORTED**<br>*(via official HGVS consensus standards)* |
| **3** | **Giardine B, van Baal S, Kaimakis P, et al.**<br>HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.<br>*Hum Mutat*. 2007;28(2):206. | **DOI:** [10.1002/humu.9479](https://doi.org/10.1002/humu.9479)<br>**PMID:** [17221864](https://pubmed.ncbi.nlm.nih.gov/17221864/)<br>**PMCID:** `UNAVAILABLE (Closed-access Wiley)` | **VERIFIED**<br>*(Crossref / PubMed)* | Live HbVar repository documentation (`globin.bx.psu.edu/hbvar/`) & abstract. 2007 print article is a 1-page update note. | **PARTIALLY SUPPORTED**<br>*(Supported via live repository; 1-page note brief)* |
| **4** | **Harrison SM, Dolinsky JS, Knight Johnson AE, et al.**<br>Clinical laboratories collaborate to resolve differences in variant interpretations submitted to ClinVar.<br>*Genet Med*. 2017;19(10):1096–1104. | **DOI:** [10.1038/gim.2017.14](https://doi.org/10.1038/gim.2017.14)<br>**PMID:** [28301460](https://pubmed.ncbi.nlm.nih.gov/28301460/)<br>**PMCID:** [PMC5600649](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600649/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary full-text article inspected via PMC5600649 (pp. 1096–1098). | **SUPPORTED**<br>*(Full text inspected)* |
| **5** | **Krusche P, Trigg L, Boutros PC, et al.**<br>Best practices for benchmarking germline small-variant calls in human genomes.<br>*Nat Biotechnol*. 2019;37(5):555–560. | **DOI:** [10.1038/s41587-019-0054-x](https://doi.org/10.1038/s41587-019-0054-x)<br>**PMID:** [30858580](https://pubmed.ncbi.nlm.nih.gov/30858580/)<br>**PMCID:** [PMC6699627](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699627/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary full-text article inspected via PMC6699627 (pp. 555–557) and GA4GH specifications. | **SUPPORTED**<br>*(Full text inspected)* |
| **6** | **Landrum MJ, Lee JM, Benson M, et al.**<br>ClinVar: improving access to variant interpretations and supporting evidence.<br>*Nucleic Acids Res*. 2018;46(D1):D1062–D1067. | **DOI:** [10.1093/nar/gkx1153](https://doi.org/10.1093/nar/gkx1153)<br>**PMID:** [29165669](https://pubmed.ncbi.nlm.nih.gov/29165669/)<br>**PMCID:** [PMC5753237](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753237/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary full-text article inspected via PMC5753237 (Table 1, p. D1064). | **SUPPORTED**<br>*(Full text inspected)* |
| **7** | **Landrum MJ, Chitipiralla S, Brown GR, et al.**<br>ClinVar: improvements to accessing data.<br>*Nucleic Acids Res*. 2020;48(D1):D835–D844. | **DOI:** [10.1093/nar/gkz972](https://doi.org/10.1093/nar/gkz972)<br>**PMID:** [31777943](https://pubmed.ncbi.nlm.nih.gov/31777943/)<br>**PMCID:** [PMC6943040](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943040/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary full-text article inspected via PMC6943040 (pp. D835–D839). | **SUPPORTED**<br>*(Full text inspected)* |
| **8** | **McLaren W, Gil L, Hunt SE, et al.**<br>The Ensembl Variant Effect Predictor.<br>*Genome Biol*. 2016;17(1):122. | **DOI:** [10.1186/s13059-016-0974-4](https://doi.org/10.1186/s13059-016-0974-4)<br>**PMID:** [27268795](https://pubmed.ncbi.nlm.nih.gov/27268795/)<br>**PMCID:** [PMC4893825](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893825/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary full-text article inspected via PMC4893825 (Table 1, pp. 3–5). | **SUPPORTED**<br>*(Full text inspected)* |
| **9** | **Morales J, Pujar S, Loveland JE, et al.**<br>A joint NCBI and EMBL-EBI transcript set for clinical genomics and research.<br>*Nature*. 2022;604(7905):310–315. | **DOI:** [10.1038/s41586-022-04558-8](https://doi.org/10.1038/s41586-022-04558-8)<br>**PMID:** [35388217](https://pubmed.ncbi.nlm.nih.gov/35388217/)<br>**PMCID:** [PMC9007741](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007741/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary author manuscript inspected via PMC9007741 (pp. 310–312). | **SUPPORTED**<br>*(Full text inspected)* |
| **10** | **O'Leary NA, Wright MW, Brister JR, et al.**<br>Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation.<br>*Nucleic Acids Res*. 2016;44(D1):D733–D745. | **DOI:** [10.1093/nar/gkv1189](https://doi.org/10.1093/nar/gkv1189)<br>**PMID:** [26553804](https://pubmed.ncbi.nlm.nih.gov/26553804/)<br>**PMCID:** [PMC4702849](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702849/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary full-text article inspected via PMC4702849 (Table 1, p. D734). | **SUPPORTED**<br>*(Full text inspected)* |
| **11** | **Rehm HL, Berg JS, Brooks LD, et al.**<br>ClinGen — the Clinical Genome Resource.<br>*N Engl J Med*. 2015;372(23):2235–2242. | **DOI:** [10.1056/NEJMsr1406261](https://doi.org/10.1056/NEJMsr1406261)<br>**PMID:** [26014595](https://pubmed.ncbi.nlm.nih.gov/26014595/)<br>**PMCID:** [PMC4474187](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474187/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary author manuscript inspected via PMC4474187 (pp. 2236–2239). | **SUPPORTED**<br>*(Full text inspected)* |
| **12** | **Richards S, Aziz N, Bale S, et al.**<br>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP.<br>*Genet Med*. 2015;17(5):405–424. | **DOI:** [10.1038/gim.2015.30](https://doi.org/10.1038/gim.2015.30)<br>**PMID:** [25741868](https://pubmed.ncbi.nlm.nih.gov/25741868/)<br>**PMCID:** [PMC4544753](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544753/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary full-text article inspected via PMC4544753 (Table 3, p. 409). | **SUPPORTED**<br>*(Full text inspected)* |
| **13** | **Stodden V, McNutt M, Bailey DH, et al.**<br>Enhancing reproducibility for computational methods.<br>*Science*. 2016;354(6317):1240–1241. | **DOI:** [10.1126/science.aah6168](https://doi.org/10.1126/science.aah6168)<br>**PMID:** [27940837](https://pubmed.ncbi.nlm.nih.gov/27940837/)<br>**PMCID:** `UNAVAILABLE (Closed-access Science)` | **VERIFIED**<br>*(Crossref / PubMed)* | Published policy text and PubMed record. Policy directly mandates reproducible workflows. | **SUPPORTED**<br>*(Policy text directly supports)* |
| **14** | **Taher AT, Weatherall DJ, Cappellini MD.**<br>Thalassaemia.<br>*Lancet*. 2018;391(10116):155–167. | **DOI:** [10.1016/S0140-6736(17)31822-6](https://doi.org/10.1016/S0140-6736(17)31822-6)<br>**PMID:** [28774421](https://pubmed.ncbi.nlm.nih.gov/28774421/)<br>**PMCID:** `UNAVAILABLE (Subscription Lancet)` | **VERIFIED**<br>*(Crossref / PubMed)* | PubMed core abstract and indexing records. Full subscription journal PDF uninspected locally. | **PARTIALLY SUPPORTED**<br>*(Epidemiology supported; print uninspected)* |
| **15** | **Thein SL.**<br>The molecular basis of $\beta$-thalassemia.<br>*Cold Spring Harb Perspect Med*. 2013;3(5):a011700. | **DOI:** [10.1101/cshperspect.a011700](https://doi.org/10.1101/cshperspect.a011700)<br>**PMID:** [23637309](https://pubmed.ncbi.nlm.nih.gov/23637309/)<br>**PMCID:** [PMC3633182](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633182/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary full-text article inspected via PMC3633182 (Figure 1, pp. 2–6). | **SUPPORTED**<br>*(Full text inspected)* |
| **16** | **Wang K, Li M, Hakonarson H.**<br>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.<br>*Nucleic Acids Res*. 2010;38(16):e164. | **DOI:** [10.1093/nar/gkq603](https://doi.org/10.1093/nar/gkq603)<br>**PMID:** [20601685](https://pubmed.ncbi.nlm.nih.gov/20601685/)<br>**PMCID:** [PMC2938201](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938201/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary full-text article inspected via PMC2938201 (Figure 1, p. 2). | **SUPPORTED**<br>*(Full text inspected)* |
| **17** | **Weatherall DJ.**<br>The inherited diseases of hemoglobin are an emerging global health burden.<br>*Blood*. 2010;115(22):4331–4336. | **DOI:** [10.1182/blood-2010-01-251348](https://doi.org/10.1182/blood-2010-01-251348)<br>**PMID:** [20233970](https://pubmed.ncbi.nlm.nih.gov/20233970/)<br>**PMCID:** [PMC2881491](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881491/) | **VERIFIED**<br>*(Crossref / PubMed / PMC)* | Complete primary full-text article inspected via PMC2881491 and ASH archive (pp. 4331–4333). | **SUPPORTED**<br>*(Full text inspected)* |

---

## 3. Discrepancies Resolved Across Manuscript and Audit Registers

During this reconciliation, every manuscript location containing discrepancies in reference identifiers or candidate associations was audited, corrected, and verified:

1. **Rehm et al. (2015) Metadata Correction:**
   - *Previous Mismatch:* Draft reference 11 and interim reports cited an invalid DOI `10.1056/NEJMp1503109`, invalid PMID `26014582`, and invalid PMCID `PMC4744716` (which belonged to a Pool-Seq paper in *Mol Ecol Resour*).
   - *Correction Applied:* Replaced with authoritative NEJM Special Report DOI **`10.1056/NEJMsr1406261`**, PMID **`26014595`**, and PMCID **`PMC4474187`** in `PHASE5_4_FINAL_MANUSCRIPT_DRAFT.md` (L415) and all audit reports.
2. **Morales et al. (2022) MANE Identifiers:**
   - *Previous Mismatch:* Earlier audits associated `PMID: 35418685` and `PMCID: PMC9645817` (which belonged to an adjacent Nature paper on haematopoietic stem cells).
   - *Correction Applied:* Resolved against DOI `10.1038/s41586-022-04558-8` to authoritative **PMID `35388217`** and **PMCID `PMC9007741`**.
3. **Giardine et al. (2007) PMID Correction:**
   - *Previous Mismatch:* Citing `PMID: 17221867` (which was for de Brouwer et al., *Hum Mutat* 28:207).
   - *Correction Applied:* Corrected to authoritative **PMID `17221864`**.
4. **Krusche et al. (2019) PMID & Full-Text Scope:**
   - *Previous Mismatch:* Citing `PMID: 30858583` (a typo) and claiming uninspected subscription text.
   - *Correction Applied:* Corrected to **PMID `30858580`** and confirmed open-access full text via **PMCID `PMC6699627`**.
5. **Weatherall (2010) PMID & PMCID:**
   - *Previous Mismatch:* Citing `PMID: 20237318` (Beekman & Touw on G-CSF).
   - *Correction Applied:* Corrected to authoritative **PMID `20233970`** and open-access **PMCID `PMC2881491`**.
6. **den Dunnen et al. (2016) PMCID Removal:**
   - *Previous Mismatch:* Interim audit line 84 had cited `PMC5089531` (an unrelated multiple sclerosis article).
   - *Correction Applied:* Removed erroneous PMCID, noting closed-access Wiley journal status, and verified claim support via official HGVS consensus specifications (`varnomen.hgvs.org`).
7. **Harrison et al. (2017) PMCID Typo:**
   - *Previous Mismatch:* Readiness audit line 87 cited `PMC5599322` (an Alzheimer's article).
   - *Correction Applied:* Corrected to authoritative open-access **PMCID `PMC5600649`**.
8. **ClinVar 3-Star Candidate Misattribution:**
   - *Previous Mismatch:* Earlier working drafts attributed the single 3-star record to `HBB-CP2-072`.
   - *Correction Applied:* Programmatic manifest inspection confirmed `HBB-CP2-072` is an exactly 2-star record (`clinvar_star_rating: 2`), while **`HBB-CP2-245`** ($c.380T>G$, $p.Val127Gly$) is the sole 3-star expert-panel record (`clinvar_star_rating: 3`). Corrected in manuscript draft lines 121 and 202.

---

## 4. Scientific Claim Boundary Checklist

Every scientific boundary condition mandated by the protocol was verified line-by-line across `PHASE5_4_FINAL_MANUSCRIPT_DRAFT.md`:

- [x] **Primary Cohort Denominator ($N = 55$):** Consistently reported as 55 across Abstract, Introduction §1.7, Methods §2.1, §2.5, §2.6, §2.7, §2.8, Results §3.1, §3.2, §3.3, §3.4, §3.7, Discussion §4.1, §4.2, Limitations §5.1, §5.2, §5.3, §5.5, and Conclusion §6.
- [x] **Conditional Concordance Scope:** The 100.00% (55/55) concordance rate is explicitly bounded to the pre-screened primary cohort and prohibited from being extrapolated to unselected clinical sequencing callsets or novel variants.
- [x] **Curation Incorporation Bias Disclosure:** Explicitly and prominently declared using exact field notation (`comparison_status == "EXACT_AGREEMENT"`) across Abstract (L20), Introduction §1.7 (L67), Methods §2.6 (L139–141), Discussion §4.2 (L333), and Limitations §5.1 (L364–367).
- [x] **Single-Database Provenance Profile:** Sole origin in ClinVar without independent secondary corroboration (`independent_non_clinvar_corroboration == "NONE"`, 55/55) explicitly acknowledged in Abstract (L20), Intro §1.7 (L67), Methods §2.5 (L122), Results §3.1 (L202), and Limitations §5.2 (L369).
- [x] **Unrepresented Mutation Classes ($n = 0$):** Explicitly declared that Classes C05 (in-frame indels/deletions), C07 (in-frame insertions/duplications), C08 (splice donor disruptions), and C10 (5' UTR regulatory) are unrepresented ($n = 0$) in the primary cohort and have zero empirical performance data (Abstract L20, Results §3.4 L251/269, Limitations §5.3 L380, Conclusion §6 L399).
- [x] **Segregation of Synthetic & Regression Experiments:** Synthetic robustness inputs (Experiment D, 18 controls, Class C12) and software regression metadata (Experiment E, 55/55 code invariance) are isolated into dedicated sections (Methods §2.10, Results §3.5–3.7) and never conflated with the external biological comparison ($A$ vs $C$).
- [x] **Boundary Protection:** Zero claims of independent biological ground truth, clinical validity, diagnostic accuracy, or clinical pathogenicity prediction. The manuscript explicitly distinguishes objective sequence translation from ACMG/AMP clinical interpretation (Intro §1.4, Methods §2.1, Discussion §4.5, Limitations §5.6).

---

## 5. Ethics and Author Declarations Checklist

### Regulatory Realities Established
The study is objectively established as a secondary in silico computational benchmark evaluating public de-identified genomic repository records from NCBI ClinVar alongside synthetic control sequences. The study involved zero human participants, zero clinical biological specimens, and zero protected health information (PHI).

### Elimination of Automatic Exemption Presumption
In accordance with research integrity standards, the manuscript draft and audit registers do **not** declare or presume an official Institutional Review Board (IRB) exemption. Because investigators cannot self-certify official regulatory status where local institutions mandate formal administrative review, institutional determination is classified strictly as an author responsibility.

### Mandatory Author Action Checklist (Required Prior to Journal Submission)
The following administrative actions must be completed by the human research team:
- [ ] **Institutional Ethics Determination:** Verify whether the authors' home institutions require a formal administrative Non-Human Subjects Research (NHSR) determination or exemption letter, and record the protocol identifier if issued.
- [ ] **Author Names & Affiliations:** Provide complete legal names, academic/clinical departments, institutions, city, and country for all co-authors.
- [ ] **Persistent Author Identifiers:** Provide verified ORCID persistent digital identifiers for all authors.
- [ ] **Corresponding Author Designation:** Designate the corresponding author and provide their official institutional email and physical postal address.
- [ ] **CRediT Contributor Roles:** Provide formal contributor role assignments across the standard 14 CRediT categories.
- [ ] **Funding & Grant Declarations:** Specify official funding agency names and grant numbers, or state that no specific external funding was received.
- [ ] **Competing Interests:** Provide standard signed competing financial and non-financial interest statements.
- [ ] **Public Repository Accession DOI:** Deposit the benchmark code, manifests, and consequence engine commit `845f595cc039e006d74237945450c7b4a9569ee6` in a public repository (e.g., Zenodo / Figshare / GitHub release) to obtain a persistent digital object identifier (DOI).

---

## 6. Frozen Artifact Protection and SHA256 Verification

Bit-for-bit SHA256 checksums were re-verified across all frozen evaluation artifacts:

```
================================================================================
CRYPTOGRAPHIC REPOSITORY ARTIFACT VERIFICATION
================================================================================
1. Primary Evaluation Dataset Manifest:
   Path:     research/manifest/phase2c_primary.json
   Expected: 39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96
   Actual:   39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96
   Status:   VERIFIED (Bit-for-bit identical)

2. Historical Development Test Manifest:
   Path:     research/manifest/frozen_test.json
   Expected: 2f6b88422b82d3f74c20f00985a34ffb5c1c78c311e4d8b584bc732cf5fc5994
   Actual:   2f6b88422b82d3f74c20f00985a34ffb5c1c78c311e4d8b584bc732cf5fc5994
   Status:   VERIFIED (Bit-for-bit identical)

3. Benchmark Protocol Specification:
   Path:     research/protocol/PHASE2C_BENCHMARK_PROTOCOL.md
   Expected: e4bad0a095cdfa8112a649f3d8a0794cf0078d218611bb965020b100ba368969
   Actual:   e4bad0a095cdfa8112a649f3d8a0794cf0078d218611bb965020b100ba368969
   Status:   VERIFIED (Bit-for-bit identical)
================================================================================
```

*Benchmark Execution Status:* Zero benchmark re-runs were conducted; production code, evaluation manifests, and stored results remain strictly immutable.

---

## 7. Final Verdict and Editorial Determination

```
================================================================================
FINAL EDITORIAL DETERMINATION:
PASS FOR AUTHOR FINALIZATION
================================================================================
```

### Epistemic Rationale:
1. **Bibliographic Completeness:** All 17 cited references have been verified against authoritative primary indexes (Crossref, PubMed, PMC). All historical identifier transcription errors (DOIs, PMIDs, PMCIDs) have been corrected in the manuscript draft and audit registers.
2. **Text-Citation Harmony:** All 48 in-text citation mentions map 100% to the 17 bibliography entries. There are zero unreferenced citations and zero unverified assertions.
3. **Epistemic Humility:** Claims for 3 citations (Clopper & Pearson 1934, Giardine et al. 2007, Taher et al. 2018) have been responsibly qualified as `PARTIALLY SUPPORTED` to reflect format and access realities.
4. **Boundary Rigor:** All scientific boundaries (cohort size $N = 55$, incorporation bias, absence of non-ClinVar corroboration, zero-count classes, control isolation, and non-claim of clinical validity) are preserved and emphasized across all sections.
5. **Regulatory Integrity:** No unverified IRB exemption is presumed. Factually established parameters are stated, and institutional determinations are designated as mandatory author actions.
6. **Submission Status:** The manuscript is **NOT cleared for journal submission** until the human authors complete the mandatory administrative actions outlined in Section 5. The work is fully cleared as **`PASS FOR AUTHOR FINALIZATION`**.
